IL126383A0 - Apo-2li and apo-3 apoptosis polypeptides - Google Patents

Apo-2li and apo-3 apoptosis polypeptides

Info

Publication number
IL126383A0
IL126383A0 IL12638397A IL12638397A IL126383A0 IL 126383 A0 IL126383 A0 IL 126383A0 IL 12638397 A IL12638397 A IL 12638397A IL 12638397 A IL12638397 A IL 12638397A IL 126383 A0 IL126383 A0 IL 126383A0
Authority
IL
Israel
Prior art keywords
apo
apoptosis
polypeptides
apoptosis polypeptides
Prior art date
Application number
IL12638397A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27089886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL126383(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL126383A0 publication Critical patent/IL126383A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL12638397A 1996-04-01 1997-03-31 Apo-2li and apo-3 apoptosis polypeptides IL126383A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62532896A 1996-04-01 1996-04-01
US71080296A 1996-09-23 1996-09-23
PCT/US1997/005230 WO1997037020A1 (en) 1996-04-01 1997-03-31 Apo-2li and apo-3 apoptosis polypeptides

Publications (1)

Publication Number Publication Date
IL126383A0 true IL126383A0 (en) 1999-05-09

Family

ID=27089886

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12638397A IL126383A0 (en) 1996-04-01 1997-03-31 Apo-2li and apo-3 apoptosis polypeptides

Country Status (7)

Country Link
US (5) US6469144B1 (de)
EP (2) EP0904366A1 (de)
JP (1) JP2000507829A (de)
AU (1) AU735200B2 (de)
CA (1) CA2249206A1 (de)
IL (1) IL126383A0 (de)
WO (1) WO1997037020A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
EP0898576A1 (de) * 1996-03-12 1999-03-03 Human Genome Sciences, Inc. Zelltoddomäne enthaltende rezeptoren
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
AU735200B2 (en) * 1996-04-01 2001-07-05 Genentech Inc. APO-2LI and APO-3 apoptosis polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
WO1998014565A1 (en) * 1996-10-04 1998-04-09 Immunex Corporation Novel receptor that causes cell death
EP1967587A1 (de) * 1997-10-10 2008-09-10 Genentech, Inc. APO-3-Liganden
US6462177B1 (en) * 1998-03-31 2002-10-08 Amgen Inc. Mammalian blood loss-induced gene, kd312
AR020101A1 (es) 1998-07-01 2002-04-10 Cancerforskingsfonden Af 1989 Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
JP2003522118A (ja) * 1999-04-22 2003-07-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド デスドメイン含有受容体
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
JP2003514031A (ja) * 1999-11-19 2003-04-15 トーマス ブイ． ティットル， Ｔｒ３特異的結合剤およびその使用のための方法
PT1290023E (pt) * 2000-03-31 2011-01-05 Aventis Pharma Inc Factor indutor do factor nuclear kb
EP1361433A3 (de) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Verfahren zur erkennung die therapeutisches Wirkung TNF
EP1575986A4 (de) * 2002-05-09 2008-07-16 Univ Rockefeller Peptide und verfahren zur steuerung des zelltods
FR2857098B1 (fr) * 2003-07-04 2006-05-05 Inst Nat Sante Rech Med Procede de mise en evidence d'un evenement moleculaire dans une cellule grace a des proteines marqueurs fluorescentes.
CA2585098C (en) 2004-10-22 2018-12-18 Revivicor, Inc. Porcine genomic kappa and lambda light chain sequences
EP2348827B1 (de) 2008-10-27 2015-07-01 Revivicor, Inc. Immunsupprimierte huftiere
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
CN103517918A (zh) 2011-03-01 2014-01-15 诺沃—诺迪斯克有限公司 拮抗性dr3配体
EP2684896A1 (de) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung
HUE035865T2 (en) 2013-03-14 2018-05-28 Bristol Myers Squibb Co Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
UA126897C2 (uk) 2015-12-01 2023-02-22 Генмаб Б.В. Антитіла проти dr5 і способи їх застосування

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US181710A (en) * 1876-08-29 Improvement in apparatus for filling comfortables
US77694A (en) * 1868-05-05 Julius wilcke
DE266710C (de)
US170203A (en) * 1875-11-23 Improvement in friction-windlasses for barrels, kegs
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3959287A (en) * 1972-07-10 1976-05-25 Syva Company Ligand determination of spin labeled compounds by receptor displacement
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4195228A (en) * 1978-05-19 1980-03-25 General Electric Company Color contrast radiographic device
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
DE3034680A1 (de) * 1980-09-13 1982-04-29 Bayer Ag, 5090 Leverkusen Verbessertes verfahren zur auftrennung von polyurethan-hydrolysaten in polyether und diamin
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
AT376465B (de) * 1981-05-06 1984-11-26 Escher Wyss Ag Walze fuer eine walzvorrichtung
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4646835A (en) * 1985-06-28 1987-03-03 Union Oil Company Of California Acidizing method
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (de) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. Transkriptionsaktivator des 780 T-DNA-Gens
AU633248B2 (en) 1987-12-21 1993-01-28 University Of Toledo, The Agrobacterium mediated transformation of germinating plant seeds
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
DK0502036T3 (da) 1989-11-22 1996-05-06 Genentech Inc Latens-associeret peptid og anvendelser herfor
US5020181A (en) * 1990-02-28 1991-06-04 Leonard Douglas R Scraping tool kit
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (de) 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
EP0723556A4 (de) 1993-10-14 2003-03-19 Immunex Corp Fas antagonisten und ihre verwendungen
WO1995011301A1 (en) 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
AU735200B2 (en) * 1996-04-01 2001-07-05 Genentech Inc. APO-2LI and APO-3 apoptosis polypeptides
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
WO1998014565A1 (en) * 1996-10-04 1998-04-09 Immunex Corporation Novel receptor that causes cell death
JP2003522118A (ja) 1999-04-22 2003-07-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド デスドメイン含有受容体
CA2384841A1 (en) * 1999-10-18 2001-04-26 Human Genome Sciences, Inc. Death domain-containing receptor polynucleotides, polypeptides, and antibodies
WO2003001788A2 (en) * 2001-06-25 2003-01-03 Redhawk Vision Inc. Video event capture, storage and processing method and apparatus

Also Published As

Publication number Publication date
US20020192729A1 (en) 2002-12-19
WO1997037020A1 (en) 1997-10-09
AU735200B2 (en) 2001-07-05
US20020146768A1 (en) 2002-10-10
CA2249206A1 (en) 1997-10-09
EP1500702A1 (de) 2005-01-26
US20080271167A1 (en) 2008-10-30
JP2000507829A (ja) 2000-06-27
US6469144B1 (en) 2002-10-22
EP0904366A1 (de) 1999-03-31
AU2598697A (en) 1997-10-22
US20060194286A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
IL126383A0 (en) Apo-2li and apo-3 apoptosis polypeptides
AU6241698A (en) Tace-like and matrilysin-like polypeptides
HUP0102535A3 (en) Cd19xcd3 specific polypeptides and uses thereof
EP1021185A4 (de) Dihydropyrimidine und ihre verwendungen.
PT1090128E (pt) Polipéptidos dependentes da vitamina k modificados
EP0894807A4 (de) GPIb-Lipidcomplex und dessen Anwendungen
EP0919237A4 (de) Induktoren der apoptose
IL129295A0 (en) Novel hedgehog-derived polypeptides
HRP970308A2 (en) Peptide derivatives
HUP9700446A3 (en) Oilsuspension-concentrate and using thereof
ZA9711156B (en) HVEM polypeptides and uses thereof
ZA976666B (en) Fusion polypeptides
GR990300043T1 (en) Lactoferrin variants and uses thereof
ZA986760B (en) Caspases and apoptosis
ZA986761B (en) Caspases and apoptosis
IL125804A0 (en) Peptide derivatives
EP0885293A4 (de) Menschliche chemokin-polypeptide.
EP1015474A4 (de) Don-1 gen und polypeptid und deren verwendungen
EP1049708A4 (de) Meth1- und meth2- polynukleotide und polypeptide
EP0883642A4 (de) Polyesteranhydride und ihre zwischenprodukte
EP1008603A4 (de) Lösliche polypeptide
PL331523A1 (en) Azolotrizines and azolopyrimidines
GB9624562D0 (en) Peptide derivatives
GB9324013D0 (en) Polypeptides
EP0939802A4 (de) spsA POLYNUKLEOTIDE UND POLYPEPTIDE